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Presentation of the conference The 30thAnnual Confer-
ence of Italian Association of Cell Cultures (AICC) was held
at Fondazione IRCCS Istituto Nazionale dei Tumori, in
Milan, on November 27–28, 2017, with the Scientific
Coordination of Claudia Chiodoni and Mario Paolo
Colombo, from the same Institute. The conference was
opened by Katia Scotlandi, President of the Italian Associ-
ation of Cell Cultures. The main objective of the conference
was to discuss the present knowledge on the role of immune
cells in the tumor microenvironment, shaped by cells pro-
moting tumor survival that could be reeducated to treat
cancer. The meeting was organized in two days with 5 the-
matic sessions, an opening and a closing lecture, with
national and international speakers. The organizers truly
thank those who took part in the conference and made the
Conference a success.
Opening lecture Michele De Palma, from École Poly-
technique Fédérale de Lausanne, Swiss Institute for Ex-
perimental Cancer Research, in Lausanne, Switzerland,
opened the 30th Annual Conference of AICC with the lec-
ture “Reprogramming the tumor immune microenviron-
ment”. His lecture revised the role of the tumor
microenvironment (TME) in the regulation of angiogen-
esis highlighting the potential vulnerabilities that could be
targeted to improve the efficacy of anti-angiogenic cancer
therapies (Fig. 1).The TME represents the primary loca-
tion where tumor cells and the host immune system inter-
act. Through interactions between chemokines and
chemokine receptors, different immune cells are recruited
into the TME where they influence tumor progression
and therapeutic outcome. De Palma reported important
findings suggesting that the manipulation of chemokine-
chemokine receptor signaling pathways could reshape the
immune and biological phenotypes of a tumor in a man-
ner that increases effectiveness of immunotherapy. Based
on recent findings, it is predicted that targeting both pro-
tumor and anti-tumor chemokine-chemokine receptor
signaling pathways, in combination with other immuno-
therapies, such as programmed cell death-protein 1 (PD-
1) and ligand 1 (PD-L1) blockade, could give clinical bene-
fit in cancer patients. In this context, De Palma addressed
the extrinsic regulation of angiogenesis by TME. Patho-
logical angiogenesis is a hallmark of cancer and a thera-
peutic target. The angiogenic programming of a tumor
tissue is a process regulated by many players such as
tumor cells together with different tumor-associated stro-
mal cells and their bioactive products, including cyto-
kines/chemokines or growth factors, the extracellular
matrix and secreted microvesicles. De Palma and co-
workers demonstrated that the combination of angiopoie-
tin-2 (ANGPT2) and vascular endothelial growth factor A
(VEGFA) blockade by a bi-specific antibody (A2V) pro-
vided therapeutic benefits, as compared to the single
agents, in both genetically-engineered and transplantable
tumor models, including metastatic breast cancer, pancre-
atic neuroendocrine tumor and melanoma. He reported
that A2V promoted vascular regression, tumor necrosis,
and antigen presentation by intratumoral phagocytes.
A2V also normalized the remaining blood vessels and fa-
cilitated the extravasation and perivascular accumulation
of activated, interferon-γ (IFNγ)–expressing CD8+ cyto-
toxic T lymphocytes (CTLs). Whereas the anti-cancer ac-
tivity of A2V was, at least in part, CTL-dependent,
perivascular T cells concurrently up-regulated the expres-
sion of the immune checkpoint PD-L1 in tumor
* Correspondence: teresadm@unicz.it
1Dept. of Experimental and Clinical Medicine, University of Catanzaro “Magna
Graecia”, Catanzaro, Italy
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Di Martino et al. Journal of Experimental & Clinical Cancer Research  (2018) 37:48 
https://doi.org/10.1186/s13046-018-0710-x
endothelial cells. IFNγ neutralization blunted this adaptive
response, and PD-1 blockade improved tumor control by
A2V in different cancer models. He concluded that im-
mune cells could be considered as key effectors of antian-
giogenic therapy and support the rationale for co-
targeting angiogenesis and immune checkpoints in cancer
therapy [1]. De Palma also reported their recent results on
the role of microRNA (miRNA) in reprogramming tumor-
associated macrophages (TAMs). He showed their recent
findings that myeloid-specific inactivation of the miRNA-
processing enzyme, DICER, promotes the functional
polarization of TAMs to a M1-like phenotype character-
ized by hyperactive IFN-γ/STAT1 signaling. This rewiring
decreased the immunosuppressive capacity of TAMs and
favored the recruitment of activated CTLs to the tumors.
CTL-derived IFN-γ exacerbated M1 polarization of
Dicer1-deficient TAMs and inhibited tumor growth. Sur-
prisingly, DICER deficiency in TAMs abrogated the anti-
tumor effects of macrophage depletion by anti-CSF1R
antibodies, and allowed complete tumor eradication by
PD-1 checkpoint blockade or CD40 agonistic antibodies.
Moreover, the group of De Palma observed that genetic
rescue of Let-7 miRNA activity in Dicer1-deficient TAMs
partially restored their M2-like phenotype and reduced
tumor-infiltrating CTLs. The findings presented by De
Palma indicated that DICER/Let-7 activity opposes IFN-γ-
induced, immunostimulatory M1-like TAM activation,
with potential therapeutic implications and suggested that,
the inhibition of Let-7 activity may provide a strategy for
reprogramming immunosuppressive TAMs into cells cap-
able of stimulating anti-tumor immunity. All together the
provocative findings presented by De Palma support the
hypothesis that the reprogramming of TAMs to an immu-
nostimulatory mode can synergize with several anti-can-
cer therapies that, either directly or indirectly, may
enhance the endogenous immune response against the
tumor [2].
Session 1
3D cultures and microfluidics: New tools for modeling
tumor—Stroma interaction
In vitro bi-dimensional (2D) cell culture models have
been extensively used to investigate tumor cell behaviors
and to assess cancer cell responsiveness to therapies.
However, 2D cell cultures represent an over-simplified
system due to the absence of the specific tumor micro-
environment context, known to be critically essential in
cancer progression. In order to overcome these limita-
tions of 2D cell models, three-dimensional (3D) cultures
and microfluidic systems have been recently developed
as “closer-to-in vivo” systems in which three-
dimensionality, structural organization and presence of
flow are accomplished. For the 3D cultures, a critical
step is the choice of matrices and scaffolds. Several types
of matrices and scaffolds of both organic and inorganic
nature are being currently employed; the most com-
monly used are agarose, collagen, fibronectin, gelatin,
laminin, and vitronectin. The choice of such matrices
Fig. 1 Adapted from De Palma et al. [19]. Manipulation of chemokine-chemokine receptor signaling pathways could reshape the immune and
biological phenotypes of a tumor in a manner that increases effectiveness of immunotherapy
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and scaffolds is mainly based on the cell type and the
specific micro-architecture needed to be obtained.
In this context, Serena Danti from University of Pisa
(Italy) clearly demonstrated that the architectural fea-
tures of the matrices influence scaffold cell colonization,
cell morphology, growth and activity. 3D cancer models
of pancreatic ductal adenocarcinoma (PDAC) were inter-
faced with different polymeric scaffolds. Fabrication of
both sponge-like matrices and fiber mesh scaffolds with
different internal architectures were obtained by using
two biocompatible polymeric formulations – poly(vinyl
alcohol)/gelatin (PVA/G) mixture and poly(ethylene
oxide terephthalate)poly(butylene terephthalate (PEOT/
PBT) copolymer – and different conventional scaffolding
techniques. Although primary PDAC cells were able to
adhere to the inner surface of both spongy-like and fiber
scaffolds and the cell viability did not significantly differ
among the different matrices, a duct-like morpho struc-
ture resembling the local advanced PDAC tissue was
obtained only when using spongy-like scaffolds. Indeed,
spongy-scaffolds enhanced also production of MMP-2,
demonstrating that these types of scaffolds supported
the generation of pancreatic tumor models with
enhanced aggressiveness [3]. Danti showed also data re-
garding a 3D in vitro model of HCC based on HepG2
liver cells seeded inside poly(vinyl alcohol) and gelatin
(PVA/G) hydrogels and cultured for up to 24 days. In
this 3D setting, HepG2 cells were viable for long term
and formed aggregates with different morphological fea-
tures and cytoskeletal organization according to their
zonal localization, thus demonstrating that this 3D HCC
model could represent a useful tool for investigating
mechanisms of tumor progression and invasion.
A relevant aspect of tumor invasion is represented by
circulatory patterns and microarchitecture of capillary
vessels. Recent advances in the generation of microvas-
cularized systems through microfluidic approaches were
nicely presented by Chiara Arrigoni, from IRCCS Istituto
Ortopedico Galeazzi of Milan (Italy). She described a
microfluidic 3D model to assess transmigration of breast
cancer cells (BCC) through micro-vessels followed by
colonization of a bone-like microenvironment, which
was made of osteo-differentiated BMSCs and hydrogel
[4]. The method was based upon polydimethylsiloxane
(PDMS) molds, needed to generate complex 3D con-
structs in which several cell types and biomaterials were
incorporated with a high spatial control. Interfaces be-
tween gels and culture medium channels were obtained
by means of PDMS microposts, allowing the formation
of microvascular networks accessible from the medium
channel itself. Moreover, the most organized vascular
network was achieved supplementing co-culture of mes-
enchymal and endothelial cells with ANG-1 and VEGF.
These studies clearly indicate that microfluidic
technologies dramatically improve the significance of in
vitro 3D biological models, and represent promising
tools to develop in vitro 3D models in which the micro-
environment and cell distribution can be spatially con-
trolled and biophysical and biochemical features can be
modulated.
Session 2
Tumor metabolism
Metabolic deregulation is an established hallmark of
cancer cells. Also in immune cells, dramatic metabolic
changes are required to effectively achieve the various
cellular functions that create a dynamic immune
response against invading pathogens and tumor cells.
Recent studies have provided mechanistic details of the
contribution of the aberrant modulation of cancer me-
tabolism in the regulation of tumor growth and response
to chemotherapy, radiotherapy and/or immunotherapy.
It is well recognized that most cancer cells enhance glu-
cose and glutamine consumption to satisfy their energy
demand and biosynthesis requirements for fast prolifera-
tion. Importantly, Warburg stated that, even in the pres-
ence of oxygen, cancer cells show increased glycolysis
using only a small fraction of glucose for oxidative phos-
phorylation (OXPHOS) [5]. More recently, it has been
reported in different tumors types that the energetic me-
tabolism of resistant cell subpopulations is either
Warburg-like or OXPHOS-addicted, with conceivable
explanation as to which metabolic phenotype could be
advantageous during tumor development and adaptation
to therapy. Some studies collectively suggest that the
type of therapy can strongly influence the metabolic
reprogramming of resistant cancer cells. Therefore, ther-
apy may have an active role in selecting resistant clones
and, depending on the mechanisms of action, drugs
might confer a high degree of plasticity to the cancer
cells, making them particularly clever in rewiring their
metabolic network (Fig. 2).
In this context, Stefano Indraccolo, from Istituto
Oncologico Veneto (Padua, Italy) clearly elucidated the
metabolic rewiring in tumors induced by anti-angiogenic
therapy, such as VEGF ligand-blocking drugs or drugs
blocking VEGFR signaling [6]. It is recognized that anti-
angiogenic therapy causes a rise in hypoxia in the
targeted tissues and subsequent HIF1α-mediated up-
regulation of several glycolysis genes, including glucose
transporter 1 (GLUT1), lactate dehydrogenase A
(LDHA), and MCT4, a lactate transporter that is often
over-expressed by cells surrounding necrotic areas in
solid cancers. In addition, HIF-1 triggers the pyruvate
dehydrogenase kinases (PDKs), which deactivate the
mitochondrial pyruvate dehydrogenase complex and
thereby decrease the flow of glucose-derived pyruvate
into the mitochondria. These data support the
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hypothesis that anti-angiogenic drugs might rewire
tumor metabolism and promote the Warburg effect. Be-
yond HIF-1, the comprehensive view of metabolic alter-
ations caused by anti-angiogenic drugs in tumors might
lead to the discovery of novel predictive biomarkers of
response. For instance, tumors bearing genetic defects in
LKB1, a kinase stimulating AMPK signaling, might
undergo metabolic crash following anti-angiogenic ther-
apy by VEGF blockade. This hypothesis is currently
explored in lung cancer, as LKB1 inactivation is rela-
tively common in this malignancy. Furthermore, some
studies underline the possible existence of intra-tumor
metabolic heterogeneity not only forced by local patho-
physiological conditions, such as hypoxia or glucose
deprivation, or adaptation to a specific environment, but
rather intrinsic to tumor cells. Indraccolo concluded that
this multifaceted metabolic heterogeneity is still poorly
described and it might be connected with the genetic
heterogeneity of solid tumors, given the proven link
between certain oncogene/tumor suppressors and me-
tabolism (such as Akt/KRAS/glycolysis and MYC/gluta-
minolysis), or, alternatively, be accounted for by
epigenetic modifications.
Recent discoveries also indicate that an important
Achilles’ heel of many types of cancer cells is their in-
capacity to adapt to starvation. While healthy cells
respond to nutrient and growth factor deficiency by acti-
vating maintenance and stress response mechanisms
that make them more resistant to diverse types of injur-
ies, including chemotherapy, this type of reaction is fre-
quently compromised in cancer cells, mainly as a
consequence of aberrant oncogene activation. Following
this view, Alessio Nencioni, from University of Genova
(Italy), outlined that starvation conditions rise the ability
of tyrosine kinase inhibitors (TKIs), as erlotinib, gefi-
tinib, lapatinib, crizotinib and regorafenib, to arrest can-
cer cell growth, to inhibit MAPK signaling and to
reinforce E2F-dependent transcription inhibition. In can-
cer xenograft models, both TKIs and cycles of fasting
slowed tumor growth, when associated, were signifi-
cantly more effective than either type of treatment alone.
He concluded that cycles of fasting or of specifically de-
signed fasting-mimicking diets should be considered in
clinical studies as a mean to enhance the action of
standard therapies [7].
Since neoplastic cell growth needs a constant supply
of lipids with balanced molecular composition to create
new cell membranes, a process dependent on de novo
synthesized fatty acids (FAs), Alessandra Carè, from Isti-
tuto Superiore di Sanità in Rome, studied the involve-
ment of stearoyl-CoA desaturases (SCDs) in tumor
progression [8]. SCDs are endoplasmic reticulum en-
zymes that catalyze the introduction of the first double
bond in the cs-Δ9-position to convert saturated FAs
(SFAs) into mono-unsaturated FAs (MUFAs). In particu-
lar, she showed that SCD5 is down-regulated in
advanced melanoma and its restored expression signifi-
cantly restricted melanoma malignancy, both in vitro
and in vivo, through a mechanism regulating the secre-
tion of extracellular matrix proteins, such as secreted
protein acidic and rich in cysteine (SPARC) and collagen
IV and of their proteases, such as cathepsin B.
Fig. 2 Cancer therapy can strongly influence the metabolic reprogramming of resistant cancer cell subpopulations. They can rewire their metabolism
towards glycolysis or OXPHOS on the basis of the type of cancer therapy
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Exogenous over-expression of SCD5 or supplementation
of its enzymatic product, oleic acid, diminished the
intracellular pH and, in turn, the vesicular trafficking
across plasma membranes, along with the spreading of
melanoma. This intracellular acidification is, at least par-
tially, due to SCD5-induced reduction of the vacuolar H
+-ATPase, a proton pump whose inhibition changes the
secretion profile of cancer cells. In addition, she demon-
strated the existence of a negative feedback loop be-
tween SCD5 and miR-221&222, in good agreement with
their opposite functions and with the less invasive more
differentiated phenotype, associated with SCD5 re-
expression in advanced melanomas. These data support
a role for SCD5 and its enzymatic product, oleic acid, in
the defense against malignancy, offering molecular de-
tails for the beneficial Mediterranean diet.
Session 3
Tumor microenvironment in hematological malignancies
In the last decades, it has become clearly evident that
components of the tumor microenvironment (TME) are
far from being mere bystander elements, but rather
actively contribute to tumor development and progres-
sion. While this concept is by now a milestone for most
solid tumors, the tumor microenvironment in
hematological malignancies is less studied.
Indeed, while the understanding of the pathogenesis
and progression of lymphomas and other hematological
malignancies has considerably advanced, due to the re-
cent high-throughput technologies, such as next-
generation sequencing, leading to the identification of
the genetic alterations and cellular pathways involved,
the relevance of the cellular context in which these
malignancies arise, has been relatively neglected in the
past years. Now, it has become clear that, also in
hematological tumors, the cross-talk between neoplastic
elements and surrounding stromal and immune cells, is
critical for tumor progression, providing survival and
proliferation signals, as well as protection from the im-
mune attack. Classic Hodgkin Lymphoma (cHL) repre-
sents an extreme example of hematological tumor in
which the tumor microenvironment is of outmost rele-
vance, being this neoplasia composed by a low number
of transformed cells surrounded by normal accessory
cells, such as macrophages and monocytes that actively
contribute in building an immunosuppressive environ-
ment. Beside cHL, many other B cell malignancies, such
as CLL (chronic lymphocytic leukemia) and DLBCL (diffuse
large B cell lymphoma) rely on support of surrounding stro-
mal and immune cells for their progression and
dissemination.
In this context Silvia Deaglio, from the University of
Turin (Italy), clearly outlined the need for CLL of a
“nursing” niche in lymphoid organs. Indeed, the survival
of leukemic cells is highly affected by the interactions
with non-leukemic cells in these permissive niches
where CLL cells subvert the normal architecture of the
lymphoid organs and recruit accessory cells, such as
stromal cells, dendritic cells and T lymphocytes, all play-
ing an active role in survival and proliferation of CLL.
Recently, several studies highlighted the role for hypoxia
in re-shaping tumor microenvironment towards immune
suppression. Accordingly, the CLL niche has been found
to be a highly hypoxic environment in which the low
oxygen tension favors the differentiation of circulating
monocytes into nursing cells characterized by the
expression of immunosuppressive markers such as IDO,
CD206, CD163, IL-10 and IL-6, all molecules contribut-
ing to the establishment of an immunosuppressive envir-
onment in which T cell response is inhibited and T
regulatory cells are expanded. These effects are, at least
in part, mediated by the adenosinergic system. In low
O2 tension, CLL cells undergo a metabolic adaptation
that increases the levels of extracellular ATP, enhancing
adenosine production and signaling through adenosine
receptors, expressed by CLL and surrounding accessory
cells. In line with this, targeting the adenosinergic axis,
may revert the effects on cell differentiation and may
open the way to specific inhibitors as a new therapeutic
strategy in CLL [9].
Beside its cellular components, the TME comprises
also a number of molecules that all together form the
extracellular matrix (ECM). ECM, once considered a
mere scaffold for the tumor to grow in size, is now being
appreciated also for its regulatory properties. Claudio
Tripodo, from the University of Palermo (Italy), ele-
gantly showed how the ECM molecules actively contrib-
ute to define the architecture of the secondary lymphoid
organs (SLO) and how changing specific ECM proteins
may alter the course of the disease. He showed that the
deficiency of the matricellular SPARC, in mice prone to
lupus-like autoimmunity (Faslpr/lpr) backcrossed to
Sparc-deficient animals, led to a higher severity of auto-
immunity that eventually resulted in the development of
a CD5+ B cell lymphoma resembling human B-CLL. On
the other hand, when Faslpr/lprmutation was transferred
to mice deficient for a different matricellular protein,
osteopontin (OPN), mice showed severe and accelerated
secondary lymphoid organ hyperplasia that evolved to a
different type of lymphoma in aged mice, characterized
by an accumulation of a non-canonical B cell popula-
tion, suggestive of a high-grade DLBCL of the Activated
B cell type.
DLBCL is a molecularly heterogeneous disease whose
genetics may have clinical implications for prognosis and
choice of treatment. However, the limited access to fresh
tumor material has hindered the use of DLBCL muta-
tional profiles for clinical practice. In such a context,
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Davide Rossi from the Institute of Oncology Research in
Bellinzona (Switzerland), proposed DLBCL genotyping
by analyzing cell-free DNA, which is released into the
blood by tumor cells undergoing apoptosis and can be
used for the identification of DLBCL mutations, clonal
evolution, and mechanisms of resistance. In particular,
NGS of plasma cfDNA of DLBCL patients has a high
sensitivity and specificity in discovering mutations, even
those that are undetectable in the tissue biopsy because
harbored in clones anatomically distant from the biopsy
site [10].
Session 4
Immunotherapy and treatment resistance
The session was dedicated to the optimization of Adoptive
T cell therapy (ACT) against cancer and to the strategies
developed to overcome the immune resistance of cancer
cells. ACT has become a promising immunotherapeutic
option for cancer patients. The proof for ACT therapeutic
efficacy was first obtained with allogenic T cells and then
reproduced with T cells isolated from patients’ tumor sam-
ples (i.e. tumor-infiltrating lymphocytes) [11]. It is now
clear that specificity of ACT products can be educated by
genetically engineering T cells with classical T Cell Recep-
tors (TCR) or chimeric antigen receptors (CAR). Anna
Mondino, from San Raffaele Hospital (Milan) described
the role played in solid tumors by the stromal barrier and/
or interference and by the presence of frequent changes in
immunogenic epitopes in the tumor due to genetic in-
stability. These tumor-related mechanisms severely limit
ACT-based approaches. It could be possible to overcome
these limitations through the concomitant immunogenic
targeting of both cancer and stroma cells. This aim can be
achieved by “dual targeting” strategies based on combin-
ation of TCR/CAR-redirected T cell products and their as-
sociation with drugs targeting tumor-vessels and/or
epigenetic modifiers, with the ability to sensitize tumors
to T cell recognition [12]. Existing data have proven syner-
gistic effects in combined settings and suggest that add-
itional benefit can be achieved by additional combinatorial
therapeutic approaches in ACT of solid tumors. Andrea
Anichini, from Fondazione IRCCS Istituto Nazionale dei
Tumori (Milan), has described the down-modulation of
T-cell antitumor effector functions by immune inhibitory
factors within the tumor microenvironment [13]. Such
molecules include cell surface proteins (such as pro-
grammed cell death 1 ligands 1 and 2(PD-L1 and PD-L2)
also called immune checkpoint inhibitors and cytokines
(such as TGF-β and IL-10). Immunomodulatory mAbs
can be used to escape from local immunosuppression
blocking suppressive receptors (such as, programmed cell-
death 1 (PD-1) or cytotoxic T-lymphocyte antigen 4
(CTLA-4). The clinical responses to these mAbs have
been relevant in the clinical setting and the results have
clearly shown that in some cases they can induce long
lasting clinical responses, significantly prolonging the sur-
vival of the patients. In addition, some malignancies in-
cluding malignant melanoma, are very sensitive to this
therapeutic strategy, while others such as pancreatic
ductal adenocarcinoma are poorly responsive. These clin-
ical evidence have pushed the investigators in searching
for biomarkers and molecular factors involved in the re-
sistance to immunotherapy with immune checkpoint-
blocking mAbs. Several findings have suggested that in
tumors the increased lymphocyte infiltration and the high
load of mutations are correlated with clinical responses to
immunecheckpoint inhibitors. This implies that the tar-
geting of cancer cells by cognate T cells activated by the
mAbs, requires an active HLA class I antigen processing
machinery (APM). Therefore, HLA class I APM compo-
nent defects can play an important role in both innate and
acquired resistance to immunotherapy with immune
checkpoint-blocking mAbs. The mechanisms determining
these defects include alterations in histone acetylation,
MAPK pathway activation, and methylation of the pro-
moters of genes encoding HLA class I APM components.
Several strategies can be exploited in order to overcome
this protective mechanism including the use of histone
deacetylase inhibitors, inhibitors of MAPK pathway acti-
vation, and demethylating agents. In this light, targeted
therapy based on BRAF- and MEK-inhibitors and im-
munotherapy with immune checkpoint inhibitors cur-
rently represents the standard of care as first-line
treatment for advanced/metastatic melanoma disease.
Such therapies induce a 3-year overall survival rate of 45%
and a 5-year overall survival rate of 30%, respectively.
Similar strategies have been successfully developed with
other target-based agents such as anti-HER2 and anti-
ALK. Another way to overcome the resistance to immune
checkpoint inhibitors is the combination of different im-
munotherapy approaches. Beyond the combined use of
the PD-1 and CTLA-4 blocking mAbs, the latter mAbs
can be also combined with other immunomodulatory
molecules, such as anti-LAG3, anti-GITR, anti-IDO, anti-
CSF and anti-OX40 Abs. While no increase in side effects
was observed, promising clinical responses were recorded
in highly pre-treated patients. Finally, Marina Garassino,
from the same Institute, illustrated the scenario opened by
the use of new immune checkpoint inhibitors showing the
role played by PD-L1 status in redirecting the response
and the survival of the patients.
Session 5
Tumor-associated immunosuppression
Tumor progression is associated with a general state of
immune suppression that acts both locally, at the tumor
site, and systemically. Several players take part in estab-
lishing such immune-suppressive environment, such as
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myeloid suppressor cells (myeloid-derived suppressor
cells/MDSCs and tumor-associated macrophages/
TAMs), regulatory T cells, inhibitory cytokines and
immune checkpoint receptors, which act in concert
with cancer cells to inhibit anti-tumor immunity.
Licia Rivoltini, from the Fondazione IRCCS Istituto
Nazionale dei Tumori in Milan, focused her talk on
MDSC in melanoma, providing mechanistic evidence for
their expansion/regulation and suggesting their feasibil-
ity as prognostic markers [14].
She described the development of an in vitro model of
MDSC generation, based on monocytes conditioned
with melanoma exosomes (EXO-MDSC) and leading to
the generation of HLA-DRlow, TGFβ/IL6/CCL2-secret-
ing immunosuppressive cells. Several miRNAs were
strongly regulated in EXO-MDSC, and were responsible
for MDSC generation and suppressive phenotype. By in
vivo experiments she showed that injection of melanoma
exosomes in mice induces accumulation and activation
of MDSC. Rivoltini’s research group also identified a
myeloid index score (MIS) in the peripheral blood
mononuclear cells that defines 4 subsets of metastatic
melanoma patients with increasing disease aggressive-
ness and worse prognosis.
The other major myeloid suppressive subset expanded
in tumor conditions, is represented by TAMs that were
clearly presented by Antonio Sica [15], from Università
del Piemonte Orientale (Novara, Italy). A plethora of evi-
dence indicate that macrophages are characterized by an
elevated functional plasticity being able to express differ-
ent functional programs in response to different microen-
vironmental signals, rendering the M1-M2 paradigm of
macrophage polarization a limited view. Nevertheless, in
general, TAMs, during tumor progression, acquire a
skewed M2 phenotype and express pro-tumor activities.
Studies from Sica’s research group provided evidence that
TAMs are characterized by a status of tolerance in re-
sponse to lipopolysaccharide (LPS) and other proinflam-
matory signals and this state is dependent on nuclear
overexpression of the p50 NF-κB inhibitory homodimer.
In agreement, they found delayed tumor progression and
increased survival in p50 NF-κB–deficient mice in both
melanoma and fibrosarcoma models. More recently his
group investigated the role of p50 NF-κB in regulating the
phenotype of TAMs in colorectal cancer (CRC). Using an
in vivo mouse model of colitis-associated cancer (CAC)
and ApcMin mice, they found that p50−/− mice displayed
exacerbated colitis but fewer and smaller tumors, and en-
hanced levels of Th1 cytokines/chemokines, such as IL-12
and CXCL10, suggesting that p50-driven inhibition of
M1-polarized gut inflammation is able to support CRC
development.
Sabina Sangaletti, from the Fondazione IRCCS Istituto
Nazionale dei Tumori in Milan (Italy) addressed the
issue of tumor-associated immune-suppression from a
different point of view, focusing on the role of the ECM
in such a context. Indeed, as already underlined by Clau-
dio Tripodo in the context of hematological malignan-
cies, the ECM exerts regulatory activities that, within the
TME, actively contribute to many aspects of tumor pro-
gression acting on both tumor and immune cells. In par-
ticular, the study of Sangaletti and colleagues showed that
ECM regulates tumor-associated immuno-suppression
through the modulation of myeloid cell features, from
their expansion, localization and functional activities [16].
The important role of ECM in tumor progression is con-
firmed by its prognostic impact, such as in case of high-
grade breast cancers (BC) in which ECM-gene profiles
correlate with clinical outcome and response to therapy.
Among the different ECM-related signatures, only the
ECM3 profile, enriched in SPARC, COL1A1, COL5A2,
LAMA4, COL6A3 and MMP11 genes, was shown to
identify breast tumors endowed with epithelial mesenchy-
mal transition (EMT) features and poor response to ther-
apy and characterize about 40% of BC. Modeling in mice
such tumors, Sangaletti showed that the re-expression of
SPARC, the leading gene of the ECM3-signature and a
master regulator of collagen deposition, in SPARC-low or
deficient BC cells, was sufficient to reproduce the main
ECM3 BC profile, including the enrichment in mesenchy-
mal features. In these tumors, the EMT program
depended on the ECM-mediated control of MDSC activity
and the recruitment of these cells at the tumor site was
functionally relevant for preserving the mesenchymal
phenotype of ECM3/SPARC-expressing BC. In the same
pre-clinical model the inhibition of MDSC suppressive
functions, through the administration of Zoledronic acid
(ZA), an aminobisphosphonate, reverted the EMT pheno-
type rendering ECM3/SPARC-expressing BC sensitive to
chemotherapy.
The last talk was held by Silvia Piconese, from the
Università La Sapienza in Rome, who introduced an-
other component of the tumor immune-suppressive en-
vironment, the regulatory T cells (Tregs), a CD4 T cell
subset physiologically involved in the suppression of un-
wanted immunity and inflammation, and pathologically
in the inhibition of anti-tumor responses. The data
showed by Piconese on human cancers, demonstrate
that Tregs accumulate in hepatic tissues affected by pre-
malignant condition (cirrhosis) or hepatocellular carcin-
oma (HCC) and that OX40, a member of TNF receptor
superfamily, is highly expressed by Tregs at the tumor
site, and promotes their expansion and stability [17].
Interestinlgy, she addressed the issue of the metabolic
routes sustaining the expansion of Tregs in cancer that
are still unknown. During an immune response, T cells
shift from oxidative to glycolytic metabolism in resting/
memory or proliferating conditions, respectively. Treg
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conversion mostly relies on oxidative metabolism, while
the expansion of pre-existing Tregs is dependent on ana-
bolic pathways, in particular cholesterol biosynthesis. In
the tumor microenvironment, glucose deprivation, be-
cause of its high consumption by neoplastic cells, leads
to functional paralysis of anti-tumor effector cells.
Therefore, it is likely that, in such hostile microenviron-
ment, Tregs, which are less susceptible to glucose
deprivation, may prevail. Using in vitro and in vivo
mouse models, her group studied Treg-intrinsic lipid
metabolism exploring the idea that Tregs critically rely
on a lipo-synthesis-fatty acid oxidation circuitry, for
their proliferation and function.
Closing lecture and remarks
The end of the meeting has been enriched by the bril-
liant talk of Jürg Schwaller (from University of Basel,
Switzerland) who has recently discovered that the cellu-
lar origin is a critical determinant in the aggressiveness
of acute myeloid leukemia (AML), as depends on the
type of precursor cell in which the genetic alteration
occurs [18]. In particular, the attention was focused on
the leukemia fusion gene which is the result of chromo-
somal translocation associated to extra-medullary tumor
infiltration and frequent relapses in humans. To perform
their studies, an inducible transgenic mouse model was
generated and it was shown MLL-AF9 expression in
long-term hematopoietic stem cells (LT-HSC) invasive
and chemo-resistant. In fact, this subtype of cells exhib-
ited clonogenic growth, accompanied by expression of
genes involved in migration and invasion in vitro. More-
over, LT-HSC-derived AML cells were highly tumori-
genic in vivo and expressed genes related to epithelial-
mesenchymal transition (EMT). Transcriptomic analysis
led to the identification of several genes, such as Evi1
and Erg, which expression is related to disease aggres-
siveness; moreover, it was demonstrated that EMT tran-
scription factor ZEB1 controls AML cell migration and
invasion. These data were confirmed in patients thus
leading to the general significance that these genes could
be useful for patient classification and represent poten-
tial biomarkers or targets for AML.
In conclusion, the 30th annual conference of Italian
Association of Cell Culture (AICC) held at the presti-
gious cancer institute “Fondazione IRCCS Istituto
Nazionale dei Tumori”, has seen more than 100 partici-
pants, mostly of them young researchers, who actively
participated in discussion. The meeting highlighted the
recent advances in the understanding the interplay be-
tween stroma component and normal cells in solid and
hematological tumors. All presentations, including in-
vited speaker and selected talks, have emphasized that
the complex network of tumor cells, immune cells, fi-
broblasts and endothelium has a key role in affecting
important aspects of cancer outcome and could provide
key diagnostic and prognostic information. Moreover,
the data about mechanisms of activation and resistance,
as well as combination approaches, are essential for the
establishment of more effective therapeutic options.
Finally, as AICC tradition dictates, young researchers
have been awarded with prizes for best posters and best
oral presentation, both as an acknowledgement of the
scientific quality of their work and to encourage them to
continue in finding new concepts for a better cure of
cancer.
We would like to thank everyone who attended this
AICC Annual Conference.
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